Enhanced Investments - Financial Portal

AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021

Published: 2021-11-05 14:06:00 ET

- The 24-week integrated results from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluated the efficacy and safety of risankizumab (SKYRIZI®) versus placebo for the treatment of active psoriatic arthritis (PsA)¹

- Treatment with risankizumab resulted in greater improvements in PsA signs and symptoms compared to treatment with placebo at week 24¹

- No new safety signals were observed¹

- Results will be featured in a plenary session at the American College of Rheumatology (ACR) Convergence 2021

NORTH CHICAGO, Ill., Nov. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab (SKYRIZI®) in adult patients with active psoriatic arthritis (PsA). The data showed that 24-weeks of treatment with risankizumab resulted in greater improvements in PsA signs and symptoms compared with placebo with no new safety signals.1 These results will be featured in an American College of Rheumatology (ACR) Convergence 2021 plenary session on Saturday, Nov. 6, from 9:45-10 a.m. CT (Abstract #0453).

"Psoriatic arthritis is a chronic, progressive and debilitating disease. These results support the potential of risankizumab to help improve joint and skin symptoms for people living with this disease and assist more people in their pursuit of reaching their treatment goals," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie.

Patients receiving risankizumab achieved higher rates of ACR20 (55.5%) than patients receiving placebo (31.3%) at week 24.1 Additionally, patients receiving risankizumab showed greater improvements in the key clinical and patient-reported outcome endpoints compared to patients receiving placebo.1

Efficacy at Week 241***
	Risankizumab 150 mg (N=707)	Placebo (N=700)
ACR20, %	55.5	31.3
HAQ-DIa, change from baseline	-0.27	-0.08
PASI 90b, %	53.2	10.0
MDA, %	25.2	10.6
Resolution of enthesitisc, %	48.4	34.8
Resolution of dactylitisd, %	68.1	51.0

ACR20, ≥ 20 improvement in American College of Rheumatology score; HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI 90, ≥90% reduction in Psoriasis Area Severity Index; MDA, minimal disease activity; PBO, placebo; RZB, risankizumab.

*** P-value

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.